SCHEMBL14879488

SCHEMBL14879488

O=C(NC1(c2ccc(Cl)cc2)CC(C(=O)O)C1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR91 A4D1P6 5/20 0.50
FAAH O00519 1/20 0.46
CXCR3 P49682 1/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
PTGS2 P35354 2/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 1/20 0.42
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CCR1 P32246 3/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
EPHX1 P07099 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14879485 0.82 WDR91 (0.42) WDR91FAAHCXCR3CCR1RAB9A
SCHEMBL16249346 0.81 WDR91 (0.53) WDR91CXCR3CES2CES1PTGS2
SCHEMBL14879817 0.81 WDR91 (0.41) WDR91FAAHCXCR3PTGS2MAPK1
SCHEMBL27995135 0.81 WDR91 (0.45) WDR91FAAHCXCR3PTGS2MAPK1
SCHEMBL28545624 0.73 NPC1 (0.50) WDR91CXCR3PTGS2POLBTP53
SCHEMBL28793250 0.72 CXCR3 (0.51) FAAHCXCR3MAPK1CYP2C19POLB
SCHEMBL14879831 0.71 PTGS2 (0.48) PTGS2
SCHEMBL17872724 0.70 WDR91 (0.41) WDR91PTGS2
SCHEMBL17872726 0.70 WDR91 (0.41) WDR91PTGS2
SCHEMBL22438959 0.70 WDR91 (0.57) WDR91CXCR3L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768491-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2016-12-21 EP disclosed
EP-2768491-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2016-12-21 EP disclosed
US-9266908-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2016-02-23 US disclosed
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed
EP-2768491-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS Mars, Incorporated (US) 2014-08-27 EP disclosed
WO-2013059437-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2013-04-25 WO disclosed
WO-2013059437-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2013-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT1 WDR91 975/4885FAAH 1444/4885CXCR3 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.